Invenomic Capital Management LP Has $20.16 Million Stock Position in Enovis Corporation $ENOV

Posted by Brenda Bartman on Jun 18th, 2026

Invenomic Capital Management LP boosted its position in shares of Enovis Corporation (NYSE:ENOV – Free Report) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 756,717 shares of the company’s stock after purchasing an additional 44,048 shares during the period. Invenomic Capital Management LP owned 1.32% of Enovis worth $20,159,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Arax Advisory Partners acquired a new stake in shares of Enovis in the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after buying an additional 1,446 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Enovis in the third quarter worth about $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in shares of Enovis in the third quarter worth about $80,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Wells Fargo & Company reduced their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Needham & Company LLC boosted their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Zacks Research cut Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Evercore reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Enovis currently has an average rating of “Moderate Buy” and an average target price of $44.50.

Check Out Our Latest Report on Enovis

Enovis Trading Down 3.5%

Shares of ENOV opened at $20.83 on Thursday. Enovis Corporation has a 12-month low of $20.55 and a 12-month high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -1.05 and a beta of 1.38. The stock’s 50-day moving average price is $23.94 and its 200 day moving average price is $24.37.

Enovis (NYSE:ENOV – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same period in the previous year, the company posted $0.81 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts predict that Enovis Corporation will post 3.65 earnings per share for the current year.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders purchased 4,200 shares of company stock valued at $92,084. Corporate insiders own 2.90% of the company’s stock.

Enovis Profile

(Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.